Entering text into the input field will update the search result below

Glioblastoma - Deadly Until Now

Sep. 15, 2020 2:30 PM ETRENB
Stengaard profile picture
Stengaard's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • First case of cure for recurring Glioblastoma since 1994.
  • difficult to assess marketopportunities.
  • technology might be used on pancreatic cancer and solid tumors.
Brain disease concept, x-ray hologram. 3D rendering
Photo by AlexLMX/iStock via Getty Images

Seraph Institute and Enochian Biosciences

Glioblastoma is a rare but deadly brain-tumor with until now absolutely minimal chances of survival - indeed longtime survival is so rare that it is described in this scientific article

A very rare case report of long-term survival: A patient operated on in 1994 of glioblastoma multiforme and currently in perfect health

Until now patients have been referred to a combination of surgery, chemotherapy and....

The results have been very disappointing

This might change now with new technology: 



The really interesting part is not the possibility to cure those poor patients, at least not from an investor-point of view - but more that the technology might be put to use in other kinds of cancers - such as small-cell-lung-cancer and  pancreatic cancer for which the market opportunities are easier to estimate. In 2020 the USA market was around 2,4 billion dollars with a steady growth. The lung-cell cancer market exceed 6,3 billion (also growing) - so the possibilities are enormous (but so is competition) 

The patient mentioned in Enochian Biosciences report is danish, I am aware that there is currently discussing between him and Danish national Broadcast (public service) about stepping forward and telling his story. 

Analyst's Disclosure: I am/we are long ENOB.

I am a shareholder since the Dandrit days. I have a significant part of my Holdings in Enochian Biosciences, and som un-listed minor danish Biotech-companies - I have been interested and invested in Biotech for two decades

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.